Why embrace them? By Chloe Sheppard, Erfan Akbraian, Andrea Bernardini & Richard Wang Advanced Therapy Medicinal Products (ATMPs) have significant potential to transform the lives of patients by delivering remarkable, durable improvements in clinical outcomes, in addition to providing long-term cost-savings to healthcare budgets. Manufacturers often face challenges with securing reimbursement and access for high-cost…
Are they as beneficial to manufacturers as they seem? By Joana Fernandes & Ashkay Kumar What are the research aims? Products that are being reviewed by the BeNeLuxA and FiNoSe joint initiatives often generate a lot of media attention and interest for those in the pharma world. But what do these initiatives actually entail, and…
Are they right for your therapy? By Maximus Rex & Nicola Allen Drug development is a long and costly process. It is not uncommon for a new drug candidate to take more than 13 years to progress from discovery to being commercially available, w i t h costs often exceeding $1 billion for the manufacturer…
“Cross border access”, “hub models”, “highly centralised access models” are only a few buzz words to refer to the pathway that enables European Union (EU) citizens to access reimbursed treatments in another member state. This pathway is particularly relevant for Advanced Therapy Medicinal Products (ATMPs) like cell & gene therapies where specialist infrastructure, controlled distribution,…
New rapid diagnostic and assessment centres are being piloted in ten areas across England in a focused approach to identify cancer early. These new centres are part of the NHS plan to meet the new faster diagnosis standard, where patients with suspected cancer should receive a diagnosis or given the all clear within 28-days. The…
The PRIority Medicines Scheme (PRIME) of the European Medicines Agency (EMA) was started two years ago to support and optimise medicine development. The scheme provides early and enhanced scientific and regulatory support to medicines that have the potential to significantly address patients’ unmet medical needs. The EMA has published their two-year review and not surprisingly more than…
Todays’ article in the Irish Times[1] highlights again that patients in Ireland continue to be denied nine drugs which are already approved for use by the National Centre of Pharmacoeconomics (NCPE). They have been waiting on average for 2 years for the Health Service Executive (HSE) to approve them for reimbursement. The drugs concerned range…
Partners4Access has announced the appointment of Alison Kneen as Vice President of International Operations to lead its rapidly expanding Market Access Orphan Drug Specialist team. Alison brings extensive international market access experience built over the last 27 years from previous roles with IQVIA; Principal and Head of Market Access Strategic Consulting, as well as during…
Free webinar will be held on Wednesday April 4 2018 at 17:00 GMT/12:00 EST/9:00 PST. Registration available at https://partners4access.com/events/gene-therapy/ PARTNERS4ACCESS has announced details of its upcoming webinar titled ` Gene Therapy – U.S. Lessons learnt from Luxturna & Kymriah’. This is the second in a three-part webinar series on Gene Therapy. This 60 min webinar…
On Rare Disease Day, we at P4A are exploring the most innovative ways to treat and cure rare diseases. This has led to the creation of a Gene Therapy Mind Map, a learning resource to understand the different types and benefits of gene therapy. What is a Gene Therapy mind map? The Gene Therapy Mind…